Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance  by Song, Zilan et al.
Institute of Materia Medica, Chinese Academy of Medical Sciences
H O S T E D  B Y Chinese Pharmaceutical Association
www.elsevier.com/locate/apsb
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2015;5(1):34–372211-3835 & 2015 Ch
Elsevier B.V.
http://dx.doi.org/10.10
nCorresponding aut
E-mail address: a
Peer review under r
Open accwww.sciencedirect.comREVIEWAlectinib: a novel second generation anaplastic
lymphoma kinase (ALK) inhibitor for overcoming
clinically-acquired resistanceZilan Song, Meining Wang, Ao ZhangnCAS Key Laboratory of Receptor Research, Synthetic Organic & Medicinal Chemistry Laboratory,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China
Received 27 October 2014; received in revised form 13 November 2014; accepted 14 December 2014KEY WORDS
Tyrosine anaplastic
lymphoma kinase;
Alectinib;
Crizotinib;
Non-small cell lung
cancer;
Resistance;
ALK mutations;
EML4-ALKinese Pharmaceutica
16/j.apsb.2014.12.00
hor. Tel./fax: þ86 2
ozhang@simm.ac.cn
esponsibility of Inst
ess under CC BY-NC-Abstract The development of inhibitors for the tyrosine anaplastic lymphoma kinase (ALK) has
advanced rapidly, driven by biology and medicinal chemistry. The ﬁrst generation ALK inhibitor
crizotinib was granted US FDA approval with only four years of preclinical and clinical testing. Although
this drug offers signiﬁcant clinical beneﬁt to the ALK-positive patients, resistance has been developed
through a variety of mechanisms. In addition to ceritinib, alectinib is another second-generation ALK
inhibitor launched in 2014 in Japan. This drug has a unique chemical structure bearing a 5H-benzo[b]
carbazol-11(6H)-one structural scaffold with an IC50 value of 1.9 nmol/L, and is highly potent against
ALK bearing the gatekeeper mutation L1196M with an IC50 of 1.56 nmol/L. In the clinic, alectinib is
highly efﬁcacious in treatment of ALK-positive non-small cell lung cancer (NSCLC), and retains potency
to combat crizotinib-resistant ALK mutations L1196M, F1174L, R1275Q and C1156Y.
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Alectinib: a novel second generation ALK inhibitor 351. EML4-ALK—an emerging oncogenic drug target
Anaplastic lymphoma kinase (ALK), a member of the insulin
receptor superfamily, was originally identiﬁed in 1994 in anaplas-
tic large-cell lymphoma (ALCL) cell lines as a tyrosine kinase
component of a chromosomal translocation1, which fuses the
entire nucleophosmin (NPM) gene on chromosome 5 to the
30-position of the ALK gene. Subsequently, more than two dozen
additional gene rearrangements or mutations have been disclosed
as different oncogenic forms of ALK across diverse tumor types,
including the echinoderm microtubule-associated protein-like 4
(EML4)-ALK in non-small cell lung cancer (NSCLC). The fusion
gene of EML4-ALK, containing the N-terminal half of EML4 and
the intracellular catalytic domain of ALK, was identiﬁed in 2007
by two independent groups2,3. Although the occurrence of this
fusion protein was found in only 5% of NSCLCs, the large number
of NSCLC patients makes EML4-ALK the most prevalent ALK
gene rearrangement, accounting for over 11,000 new occurrences
per year in the USA4.
The landmark discovery of EML4-ALK as an oncogene was
reported by Soda et al.3 in 2007, who found that mouse 3T3
ﬁbroblasts forced to express this human fusion tyrosine kinase
generated transformed foci in culture and subcutaneous tumors in
nude mice. Clinically, the patient population harboring epidermal
growth factor receptor (EGFR) mutations was found to have no
overlap with the population harboring the EML4-ALK fusion gene,
suggesting that EML4-ALK-positive cancer represents a distinct
subclass of NSCLC. Therefore, targeting EML4-ALK may pro-
vide a new strategy to treat the subclass of NSCLC patients, for
whom current treatments are poorly effective5,6.2. First-generation ALK inhibitor and its acquired resistance
Crizotinib, a 3,5-disubstituted 2-aminopyridine (PF-2341066)
developed by Pﬁzer as a c-Met inhibitor initially, was identiﬁed
as a potent ALK inhibitor and advanced rapidly in the clinic7,8.
It received fast-track FDA approval in 2011 as the ﬁrst generation
ALK inhibitor (Xalkori™) for the treatment of advanced non-
small cell lung cancer (NSCLC) harboring ALK rearrangements. In
clinical studies, crizotinib showed an objective response rate
(ORR) of 60% and a median progression-free survival (PFS) of
9.7 months9. However, the early success of this drug was
shadowed by disease relapses in the majority of crizotinib-
treated patients within one year, under various mechanisms
including ALK fusion gene ampliﬁcation, secondary ALK kinase
domain mutations, activation of bypass signaling pathways
(EGFR, c-Kit), and others.
The development of secondary kinase mutations clustering
around the ATP binding site of the EML4-ALK rearrangement
is likely the most important mechanism underling the resistance
to crizotinib10–12. L1196M and C1156Y were the earliest two
secondary ALK mutations conferring resistance to crizotinib
identiﬁed clinically. The L1196M mutation corresponds to the
‘gatekeeper’ mutation, whereas the C1156Y mutation is located in
the αC-helix near the upper edge of the ATP-binding site. The
former mutation is analogous to the mutation T315I in ABL and
the mutation T790M in EGFR, where the original amino acid
moiety was replaced with a bulky one to interfere with the binding
of an inhibitor. However, unlike the well-established T790M
mutation that accounts for the majority of the secondary EGFR
mutations of the acquired resistance, the resistance to crizotinib ismuch more complicated, and a large number of other mutations
with a similar frequency of occurrence is found later in different
resistant patients, including G1269A, L1152R, G1202R, F1174C,
I1171T, S1206Y and the T1151 insertion (1156T-ins). These
secondary mutations account for roughly one-third of the acquired
resistance of currently discovered crizotinib-resistant patients.
Therefore, development of new generation ALK inhibitors to
combat the acquired resistance to crizotinib treatment is of urgent
need13,14.3. Alectinib—a novel second generation ALK inhibitor to
combat resistance
To date, several structurally distinct small molecules have been
developed as second generation ALK inhibitors, including LDK-
378 (ceritinib), CH-5424802 (alectinib), PF-06463922, X-396,
AP26113 and TSR-01113–15. On April 29, 2014, the FDA granted
ceritinib accelerated approval for the treatment of patients with
ALK-positive metastatic NSCLC who experience disease progres-
sion or who are intolerant to crizotinib (Fig. 1) 16,17. Very recently,
the Japanese Ministry of Health, Labor and Welfare (MHLW)
approved alectinib for the treatment of people living with NSCLC
that is ALK fusion gene-positive (ALKþ) (Fig. 1). Although most
of the new inhibitors were not originally designed to target the
secondary mutations conferring the resistance to crizotinib treat-
ment, they were highly potent against both wild and mutant ALK
kinases.
Alectinib is a unique second generation ALK inhibitor bearing
a 5H-benzo[b]carbazol-11(6H)-one structural scaffold, initially
developed by the Japanese company Chugai (a subsidiary of
Roche). It originated from the company's high throughput screen-
ing program and contains a naphtha-[2,3-b]benzofuran-11(6H)-one
framework. Replacement of the benzofuran fragment with an
indole moiety, followed by optimization of the solvent interaction
region as well as adjustment of the E0 region of the ATP binding
site to improve the kinase potency, selectivity and the pharmaco-
kinetic properties, led to the compound alectinib (Fig. 1)18,19.
It inhibited ALK with an IC50 value of 1.9 nmol/L and showed
higher selectivity for ALK than for a number of other serine/
tyrosine kinases. More importantly, alectinib also inhibited the
ALK gatekeeper mutation L1196M with an IC50 of 1.56 nmol/L.
Although the co-crystallization of alectinib with L1196M mutant
was not reported, its structure with wild ALK kinase showed that
the C3-cyano moiety has a critical role to interact with the kinase
by forming H-bonds and CH/π hydrophobic interactions. In the
KARPAS-299 (lymphoma), NB-1 (neuroblastoma) and NCI-
H2228 (lung cancer) ALK-positive cell lines, alectinib inhibited
cell proliferation with IC50 values of 3, 4.5 and 53 nmol/L,
respectively19,20. It is an ATP-competitive ALK inhibitor, and
dose-dependently inhibited EML4-ALK positive NCI-H2228
xenograft model at doses ranging from 2 to 20 mg/kg p.o.,
q.d. Signiﬁcant efﬁcacy was also achieved in the EML4-ALK
L1196M-driven tumors20.
Since 2010, clinical trials with alectinib were started in ALK
positive patients with locally advanced or metastatic NSCLC in the
US. In a multicentre, single-arm, open-label, phase I–II study in
Japan, patients with ALK-rearranged advanced NSCLC were
recruited and given alectinib orally twice daily. In the phase I
setting, 24 patients were treated at doses of 20–300 mg twice
daily, and no dose-limiting toxicities (DLTs) or adverse events of
grade 4 were observed. In the phase II setting with alectinib dosed
Figure 2 ALK is on the high-speed train.
Figure 1 Chemical structures of approved ALK inhibitors.
Zilan Song et al.36at 300 mg twice daily, almost 94% of patients achieved an
objective response and early reduction in tumor size of at least
30% was noted in most patients within the ﬁrst 6 weeks. The
proportion of patients who achieved an objective response for
alectinib is substantially higher than that of crizotinib (60.8% and
53%) in two separate early phase trials. Since 2012, phase I and
phase II a studies were conducted in patients who had failed
treatment with crizotinib and two dose-limiting toxicities were
observed in the 900 mg BID cohort. An overall response rate of
59% was reached with one complete response and 14 conﬁrmed
partial responses (PRs). A randomized, active-controlled, open-
label, phase III study was initiated in July 2014 in the US,
Australia, Europe and many other countries with treatment-naive
ALK-positive advanced NSCLC21.
The Japanese Ministry of Health, Labor and Welfare (JMHLW)
granted alectinib Orphan Drug designation in 2013, and Chugai
ﬁled an NDA with the JMHLW for ALK fusion gene-positive
NSCLC. Alectinib was quickly reviewed by the Japanese Phar-
maceutical Affairs and Food Sanitation Council's Second Com-
mittee on Drugs and received the NDA's approval within two
months. This led to approval of alectinib in September 2014 in
Japan for ALK-positive NSCLC.4. Conclusions and perspectives
The development of inhibitors for ALK has been advanced rapidly
through biology, and medicinal chemistry. The ﬁrst generationALK inhibitor crizotinib received FDA approval with only four
years of preclinical and clinical testing since the discovery of the
tumor-addicted oncogene EML4-ALK. The year of 2014 has been
very fruitful with the launch of the two second generation ALK
inhibitors ceritinib and alectinib (Fig. 2). In comparison with
crizotinib, both ceritinib and alectinib are highly potent and
selective against ALK in vitro and in vivo. Notably, the Novartis
drug ceritinib effectively inhibits ALK harboring L1196M,
G1269A, I1171T and S1206Y, but is ineffective in G1202R and
F1174C, the other two crizotinib-resistant ALK mutations. The
newly approved Roche drug alectinib is effective with crizotinib-
resistant ALK mutations L1196M, F1174L, R1275Q and C1156Y.
Alectinib: a novel second generation ALK inhibitor 37In view of the wide spectrum of ALK mutations identiﬁed after
crizotinib treatment, more second generation ALK inhibitors with
efﬁcacy against other mutations will be needed. Meanwhile,
development of new inhibitors with the capacity to penetrate the
central nervous system (CNS) also would be important, since
many lung cancers will eventually spread to the brain. Although
the ﬁnal outcome of these second generation ALK inhibitors has to
wait for the beneﬁt of a larger sample size of patients, more and
more inhibitors are already on the way.
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